Search the Newsreel

Pulse Biosciences (PLSE) Is Up 5.0% After Wider Losses And $75M ATM Plan Filed – Has The Bull Case Changed?

Thermo Fisher (TMO) Stock May Be 8% Below Fair Value On Microbiology Sale

Thermo Fisher Scientific (TMO) stock has gained 20.7% over the last year and appears modestly undervalued by about 7.6% according to a Discounted Cash Flow (DCF) model, suggesting it's close to its intrinsic value. While a recent sale of its microbiology business and focus …

Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings?

Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings? Over the last six months, Gilead Sciences's shares have sunk to $137.77, producing a disappointing 11.3% loss - a stark contrast to the S&P 500's 13.1% gain. This might have investors contemplating their next …

Pulse Biosciences (PLSE) Stock Looks Pricey On Book Value Yet Strong On Returns

Die Gilead-Sciences-Aktie steigt nach starken Q2-Zahlen und Anlegerzuflüssen

Die Edwards-Lifesciences-Aktie steigt nach starken Quartalszahlen und optimistischer Prognose

(PLSE) Risk Channels and Responsive Allocation

This article provides an in-depth AI-driven analysis for Pulse Biosciences Inc (NASDAQ: PLSE), highlighting strong sentiment across all horizons and compelling upside potential. It details institutional trading strategies with specific entry zones, targets, and stop losses for position trading, momentum breakout, and risk hedging. …

Will Gilead’s AI-Driven ADC Research with Nucleai Refine Its Oncology Strategy and Valuation Story (GILD)?

Gilead Sciences is partnering with Nucleai for AI-powered tissue analytics to enhance its antibody-drug conjugate (ADC) clinical development and precision oncology efforts. This collaboration supports Gilead's long-term strategy to pivot into oncology, leveraging its strong HIV core business. However, despite the potential of AI-enabled …

Die Boston-Scientific-Aktie stabilisiert sich nach starken Quartalszahlen

Summit Global Investments Buys New Shares in Gilead Sciences, Inc. $GILD

Summit Global Investments initiated a new position in Gilead Sciences, acquiring 11,712 shares valued at $1.48 million during the second quarter. Gilead Sciences reported strong Q2 earnings, surpassing revenue and EPS expectations, with a 10.6% year-over-year revenue increase and declared a quarterly dividend of …

Simplify Asset Management Inc. Buys 5,670 Shares of Thermo Fisher Scientific Inc. $TMO

Simplify Asset Management Inc. increased its stake in Thermo Fisher Scientific Inc. (TMO) by 32.6% in the second quarter, purchasing 5,670 additional shares. This brings their total holding to 23,079 shares, valued at approximately $11.6 million. Institutional investors collectively own 89.23% of TMO, with …

Union Bancaire Privee UBP SA Grows Stock Holdings in Thermo Fisher Scientific Inc. $TMO

HM Payson & Co. Sells 20,885 Shares of Thermo Fisher Scientific Inc. $TMO

HM Payson & Co. reduced its stake in Thermo Fisher Scientific Inc. by 11.3%, selling 20,885 shares but still holding 163,790 shares valued at $82.1 million. Despite insider selling of over $30.6 million in the last 90 days, Thermo Fisher reported strong quarterly results …

Is Alto Neuroscience (ANRO) Fully Valued As ALTO 207 Expands With New Funding?

Thermo Fisher Scientific: Biopharma Recovery And Share Gains Support The Upside (NYSE:TMO)

Thermo Fisher Scientific Inc. $TMO Shares Sold by Wedge Capital Management L L P NC

Wedge Capital Management L L P NC significantly reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 93.3% in the second quarter, selling over 11,000 shares. Despite this, other institutional investors either increased or initiated stakes in the company, with institutional ownership remaining …

Centric Wealth Management Takes $3.52 Million Position in Gilead Sciences, Inc. $GILD

Centric Wealth Management has acquired a new stake of 26,506 shares in Gilead Sciences, Inc. (NASDAQ:GILD), valued at approximately $3.52 million during the second quarter. This move is part of broader institutional interest, with 83.67% of Gilead's stock owned by institutional investors and hedge …

Quantinno Capital Management LP Purchases 36,144 Shares of Castle Biosciences, Inc. $CSTL

Quantinno Capital Management LP significantly increased its stake in Castle Biosciences, Inc. (NASDAQ:CSTL) by 387.3% in the first quarter, acquiring an additional 36,144 shares. This brings their total holdings to 45,476 shares, valued at approximately $1.12 million. While institutional investors own a large portion …

Cornerstone Capital Inc. Purchases New Position in Gilead Sciences, Inc. $GILD

Cornerstone Capital Inc. has acquired a new stake in Gilead Sciences, Inc., purchasing 36,158 shares valued at approximately $4.57 million during the second quarter. This move comes as institutional investors and hedge funds collectively own 83.67% of the company. Gilead recently reported stronger-than-expected quarterly …

Ciena Corporation $CIEN Shares Purchased by Empowered Funds LLC

Empowered Funds LLC increased its stake in Ciena Corporation ($CIEN) by 26.6% in the first quarter, holding over 20,000 shares valued at approximately $8 million. Institutional investors and hedge funds collectively own a significant 91.99% of Ciena, which maintains a "Moderate Buy" consensus rating …

Bank Hapoalim BM Makes New $1.78 Million Investment in Edwards Lifesciences Corporation $EW

Bank Hapoalim BM has invested $1.78 million in Edwards Lifesciences Corporation by purchasing 19,640 shares. This comes as other institutional investors have also adjusted their holdings in the medical research company. Analysts maintain a "Moderate Buy" rating for Edwards Lifesciences, with a consensus target …

Harmony Biosciences Holdings (HRMY), Why Is It Getting Fresh Attention?

Pulse Biosciences (PLSE) Prices A $75 Million Offering, Is The Stock Fully Valued?

Pulse Biosciences (PLSE) recently announced a $75 million at-the-market equity offering and reported wider second-quarter losses, impacting existing shareholders. Despite strong recent share price performance, with a 30-day return of 55.30% and a year-to-date return of 232.64%, the stock now trades above the latest …

Viyash Scientific profit doubles in Q1FY27; eyes Italy deal

Cytek (CTKB) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer - Wenbin Jiang Chief Financial Officer - William McCombe Investor Relations - Mark Meehan Full Conference Call Transcript Operator: Hello, and thank you for standing …

Harmony Biosciences (NASDAQ:HRMY) Rating Increased to Strong-Buy at Wall Street Zen

Wall Street Zen has upgraded Harmony Biosciences (NASDAQ:HRMY) from a "buy" to a "strong-buy" rating. This upgrade comes as the company reported strong quarterly earnings, beating analyst estimates with an EPS of $1.28 and a 30.3% year-over-year revenue increase to $261.28 million. Despite this, …

What Arcus Biosciences (RCUS)'s Steep Revenue Drop and 2026 Guidance Cut Means For Shareholders

Why Cogent Biosciences (COGT) Is Down 10.5% After Reporting Wider First-Half 2026 Losses – And What's Next

Nectar Lifesciences Publishes Q1 FY2026 Results in Press and Online

Why Alto Neuroscience (ANRO) Is Up 13.5% After Expanding ALTO-207 Phase 3 And Securing New Funding

Alto Neuroscience (ANRO) saw a 13.5% stock increase after expanding its ALTO-207 Phase 3 trial for treatment-resistant depression and securing approximately $100 million in new funding. Despite ongoing net losses, the company aims to validate its data-driven approach, with short-term focus on the expanded …

Trading the Move, Not the Narrative: (INBX) Edition

This article provides an in-depth analysis of Inhibrx Biosciences Inc (INBX), highlighting strong sentiment across all time horizons and an exceptional 100.9:1 risk-reward setup. It outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide trading decisions.

Ck Life Sciences Int'l., (Holdings) - LSI - Stock Price & News

How Investors Are Reacting To Forte Biosciences (FBRX) Widening Losses But Slightly Improved Per-Share Results

Forte Biosciences reported increased net losses in Q2 and H1 2026 but saw a slight improvement in basic loss per share due to share count adjustments. The company's investment narrative is now heavily tied to its pending sale to argenx and the cash tender …